HomeMarch
Anaveon to present first clinical data from the Phase I/II study of ANV419 at the AACR Annual Meeting 2022

Anaveon to present first clinical data from the Phase I/II study of ANV419 at the AACR Annual Meeting 2022

by | Mar 9, 2022 | Press Releases

Anaveon, a clinical-stage immuno-oncology company, today announced that it will present first clinical data from the ongoing Phase I/II study of ANV419, a powerful and selective interleukin-2 (IL-2) agonist in patients with solid tumors, in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting in New Orleans, Louisana, April 8 to April 13, 2022.